Vagus Nerve Stimulation

Current Behavioral Neuroscience Reports

Volumn 1, Issue 2, 2014, Pages 64-73

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cytokines; Depression; Epilepsy; Heart failure; Immune system; Inflammation; Metabolic syndrome; Transcutaneous vagus nerve stimulation; Treatment resistant depression; Vagus nerve; Vagus nerve stimulation

Indexed keywords

EID: 84904416596     PISSN: None     EISSN: 21962979     Source Type: Journal    
DOI: 10.1007/s40473-014-0010-5     Document Type: Article

References (90)

1. Ruffoli R, Giorgi FS, Pizzanelli C, et al. The chemical neuroanatomy of vagus nerve stimulation. J Chem Neuroanat. 2011;42:288–96. This paper provides an overview of the neuroanatomy and neurochemistry relevant to the therapeutic uses of vagus nerve stimulation. DOI: 10.1016/j.jchemneu.2010.12.002
2. Zagon A. Does the vagus nerve mediate the sixth sense? Trends Neurosci. 2001;24(11):671–3. DOI: 10.1016/S0166-2236(00)01929-9
3. Krahl SE. Vagus nerve stimulation for epilepsy: a review of the peripheral mechanisms. Surg Neurol Int. 2012;3(Suppl S1):47–52. This paper reviews the peripheral neuroanatomy and physiology of the vagus nerve that is relevant to the antiseizure effects of vagus nerve stimulation. DOI: 10.4103/2152-7806.91610
4. Lanska DJ. Corning and vagal nerve stimulation for seizures in the 1880s. Neurology. 2002;58:452–9. DOI: 10.1212/WNL.58.3.452
5. Zabara J. Inhibition of experimental seizures in canines by repetitive vagal stimulation. Epilepsia. 1992;33(6):1005–12. DOI: 10.1111/j.1528-1157.1992.tb01751.x
6. Stancak A, Kuna M, Srinivasan, et al. KapalabhatiL yogic cleansing exercise. II. EEG topography analysis. Homeost Health Dis. 1991;3(4):182–9.
7. Stancak A, Pfeffer D, Hrudova L, et al. Electroencephalographic correlates of paced breathing. Neuroreport. 1993;4(6):723–6. DOI: 10.1097/00001756-199306000-00031
8. Morris GL, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy. Neurology. 2013;81:1453–9. This is the most recent critical evaluation of evidence regarding the efficacy and safety of vagus nerve stimulation for epilepsy in children, adolescents, and adults. DOI: 10.1212/WNL.0b013e3182a393d1
9. Howland RH, Shutt LS, Berman SR, et al. The emerging use of technology for the treatment of depression and other neuropsychiatric disorders. Ann Clin Psychiatry. 2011;23:48–62.
10. Terry RS, Tarver WB, Zabara J. The implantable neurocybernetic prosthesis system. Pacing Clin Electrophysiol. 1991;14(1):86–93. DOI: 10.1111/j.1540-8159.1991.tb04052.x
11. Gorny KR, Bernstein MA, Watson RE. 3 Tesla MRI of patients with vagus nerve stimulator: initial experience using a T/R head coil under controlled conditions. J Magn Reson Imaging. 2010;31:475–81. DOI: 10.1002/jmri.22037
12. De Ferrari GM, Schwartz PJ. Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions. Heart Fail Rev. 2011;16:195–203. This paper describes the preclinical and clinical background relevant to the therapeutic use of right cervical vagus nerve stimulation for heart failure. DOI: 10.1007/s10741-010-9216-0
13. De Ferrari GM, Crijns HJGM, Borggrefe M, et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. 2011;32:847–55. This paper describes the results from the first phase II clinical trial of right cervical vagus nerve stimulation for heart failure. DOI: 10.1093/eurheartj/ehq391
14. Ben-Menachem E, Rydenhag B, Silander H. Preliminary experience with a new system for vagus nerve stimulation for the treatment of refractory focal onset seizures. Epilepsy Behav. 2013;29:416–9. DOI: 10.1016/j.yebeh.2013.08.014
15. Ellrich J. Transcutaneous vagus nerve stimulation. Eur Neurol Rev. 2011;6(4):254–6. This paper briefly describes the neuroanatomy of the auricular branch of the vagus nerve and the rationale for a transcutaneous form of vagus nerve stimulation.
16. Dietrich S, Smith J, Scherzinger C, et al. A novel transcutaneous vagus nerve stimulation leads to brainstem and cerebral activations measured by functional MRI. Biomed Tech (Berlin). 2008;53:104–11. DOI: 10.1515/BMT.2008.022
17. Kraus T, Hosl K, Kiess O, et al. BOLD fMRI deactivation of limbic and temporal brain structures and mood enhancing effect by transcutaneous vagus nerve stimulation. J Neural Transm. 2007;114:1485–93. DOI: 10.1007/s00702-007-0755-z
18. Kraus T, Kiess O, Hosl K, et al. CNS BOLD fMRI effects of sham-controlled transcutaneous electrical nerve stimulation in the left outer auditory canal: a pilot study. Brain Stimul. 2013;6:798–804. This paper describes the findings from an fMRI imaging study of the effects of transcutaneous stimulation of the outer auditory canal, demonstrating changes in limbic areas. DOI: 10.1016/j.brs.2013.01.011
19. Ventureyra EC. Transcutaneous vagus nerve stimulation for partial onset seizure therapy. A new concept. Childs Nerv Syst. 2000;16:101–2. DOI: 10.1007/s003810050021
20. Busch V, Zeman F, Heckel A, et al. The effect of transcutaneous vagus nerve stimulation on pain perception: an experimental study. Brain Stimul. 2013;6:202–9. DOI: 10.1016/j.brs.2012.04.006
21. Lehtimaki J, Hyvarinen P, Ylikoski M, et al. Transcutaneous vagus nerve stimulation in tinnitus: a pilot study. Acta Otolaryngol. 2013;133:378–82. DOI: 10.3109/00016489.2012.750736
22. Stefan H, Kreiselmeyer G, Kerling F, et al. Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial. Epilepsia. 2012;53(7):e115–8. This paper describes the findings from a pilot study of transcutaneous auricular vagus nerve stimulation in adults with refractory epilepsy. DOI: 10.1111/j.1528-1167.2012.03492.x
23. He W, Jing X, Wang X, et al. Transcutaneous auricular vagus nerve stimulation as a complementary therapy for pediatric epilepsy: a pilot trial. Epilepsy Behav. 2013;28:343–6. This paper describes the results of a pilot study of transcutaneous auricular vagus nerve stimulation for epilepsy in children. DOI: 10.1016/j.yebeh.2013.02.001
24. Peijing R, Aihua L, Jianguo Z, et al. An alternative therapy for drug-resistant epilepsy: transcutaneous auricular vagus nerve stimulation. Chin Med J. 2014;127(2):300–4.
25. Hein E, Nowak M, Kiess O, et al. Auricular transcutaneous electrical nerve stimulation in depressed patients: a randomized controlled pilot study. J Neural Transm. 2013;120:821–7. This paper describes the findings from a pilot study of transcutaneous vagus nerve stimulation for non-chronic non-refractory major depression. DOI: 10.1007/s00702-012-0908-6
26. Hassanzadeh R, Jone JC, Ross EL. Neuromodulation for intractable headaches. Curr Pain Headache Rep. 2014;18:392. doi:10.1007/s11916-013-0392-1. DOI: 10.1007/s11916-013-0392-1
27. George MS, Rush AJ, Sackeim HA, Marangell LB. Vagus nerve stimulation (VNS): utility in neuropsychiatric disorders. Int J Neuropsychopharmacol. 2003;6:73–83. DOI: 10.1017/S1461145703003250
28. Krahl SE, Senanayake SS, Pekary AE, Sattin A. Vagus nerve stimulation (VNS) is effective in a rat model of antidepressant action. J Psychiatr Res. 2004;38:237–40. DOI: 10.1016/j.jpsychires.2003.11.005
29. Furmaga H, Shah A, Frazer A. Serotonergic and noradrenergic pathways are required for the anxiolytic-like and antidepressant-like behavioral effects of repeated vagal nerve stimulation in rats. Biol Psychiatry. 2011;70:937–45. DOI: 10.1016/j.biopsych.2011.07.020
30. Kosel M, Brockmann H, Frick C, et al. Chronic vagus nerve stimulation for treatment-resistant depression increases regional cerebral blood flow in the dorsolateral prefrontal cortex. Psychiatry Res. 2011;191:153–9. A recent brain imaging study of the effects of invasive left cervical vagus nerve stimulation in patients with treatment resistant depression. DOI: 10.1016/j.pscychresns.2010.11.004
31. Conway CR, Chibnall JT, Gebarea MA, et al. Association of cerebral metabolic activity changes with vagus nerve stimulation antidepressant response in treatment-resistant depression. Brain Stimul. 2013;6:788–97. A recent brain imaging study investigating correlations between cerebral metabolic activity and the treatment response to left cervical vagus nerve stimulation. DOI: 10.1016/j.brs.2012.11.006
32. Furmaga H, Carreno FR, Frazer A. Vagal nerve stimulation rapidly activates brain-derived neurotrophic factor receptor TrkB in rat brain. PLoS ONE. 2012;7(5):e34844. doi:10.1371/journal.pone.0034884. DOI: 10.1371/journal.pone.0034844
33. Gebhardt N, Bar KJ, Boettger MK, et al. Vagus nerve stimulation ameliorated deficits in one-way active avoidance learning and stimulated hippocampal neurogenesis in bulbectomized rats. Brain Stimul. 2013;6:78–83. DOI: 10.1016/j.brs.2012.01.009
34. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000;47:276–86. DOI: 10.1016/S0006-3223(99)00304-2
35. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713–28. DOI: 10.1016/S0893-133X(01)00271-8
36. Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry. 2002;51:280–7. DOI: 10.1016/S0006-3223(01)01343-9
37. Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry. 2005;66:1097–104. DOI: 10.4088/JCP.v66n0902
38. Dunner DL, Rush AJ, Russell JM, et al. Prospective long-term multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67:688–95. DOI: 10.4088/JCP.v67n0501
39. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized controlled acute phase trial. Biol Psychiatry. 2005;58:347–54. DOI: 10.1016/j.biopsych.2005.05.025
40. Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58:355–63. DOI: 10.1016/j.biopsych.2005.05.024
41. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58:364–73. DOI: 10.1016/j.biopsych.2005.07.028
42. Nierenberg AA, Alpert JE, Gardner-Schuster EE, et al. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry. 2008;64(6):455–60. DOI: 10.1016/j.biopsych.2008.04.036
43. Schlaepfer TE, Frick C, Zobel A, et al. Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol Med. 2008;38:651–61. DOI: 10.1017/S0033291707001924
44. Bajbouj M, Merkl A, Schlaepfer TE, et al. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. J Clin Psychopharmacol. 2010;30:273–81. DOI: 10.1097/JCP.0b013e3181db8831
45. Aaronson ST, Carpenter LL, Conway CR, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul. 2013;6:631–40. This paper describes the results of a recent large randomized clinical trial comparing outcomes for three different stimulation doses of left cervical vagus nerve stimulation in patients with treatment resistant depression. DOI: 10.1016/j.brs.2012.09.013
46. Muller HH, Kornhuber J, Maler JM, Sperling W. The effects of stimulation parameters on clinical outcomes in patients with vagus nerve stimulation implants with major depression. J ECT. 2013;29:e40–2. DOI: 10.1097/YCT.0b013e318290f7ed
47. Berry SM, Broglio K, Bunker M, et al. A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. Med Devices (Auckl). 2013;6:17–35. This paper describes the findings from an analysis of patient-level data from six large prospective studies of left cervical vagus nerve stimulation compared with treatment-as-usual for treatment resistant depression.
48. Olin B, Jayewardene AK, Bunker M, Moreno F. Mortality and suicide risk in treatment-resistant depression: an observational study of the long-term impact of intervention. PLoS ONE. 2012;7(10):e48002. doi:10.1371/journal.pone.0048002. This paper describes the initial findings from a vagus nerve stimulation therapy registry of patients with treatment resistant depression. DOI: 10.1371/journal.pone.0048002
49. Gerson R, Murray E, Price B, et al. Mania following vagus nerve stimulation: a case report and review of the literature. Epilepsy Behav. 2011;20:138–40. This paper provides a brief literature review of the risk of mania associated with vagus nerve stimulation. DOI: 10.1016/j.yebeh.2010.11.005
50. Feldman RL, Dunner DL, Muller JS, Stone DA. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. J Med Econ. 2013;16(1):62–74. doi:10.3111/136969987.2012.724745. DOI: 10.3111/13696998.2012.724745
51. Rong PJ, Fang JL, Wang LP, et al. Transcutaneous vagus nerve stimulation for the treatment of depression: a study protocol for a double blinded randomized clinical trial. BMC Complement Alternat Med. 2012;12:255. doi:10.1186/1472-6882-12-255. DOI: 10.1186/1472-6882-12-255
52. Rugulies R. Depression as a predictor for coronary heart disease: a review and meta-analysis. Am J Prev Med. 2002;23:51–61. DOI: 10.1016/S0749-3797(02)00439-7
53. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res. 2002;53:897–902. DOI: 10.1016/S0022-3999(02)00311-2
54. Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs. 2009;23(7):583–602. DOI: 10.2165/00023210-200923070-00004
55. Li W, Olshansky B. Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. Heart Fail Rev. 2011;16:137–45. DOI: 10.1007/s10741-010-9184-4
56. Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension. 2012;59:755–62. DOI: 10.1161/HYPERTENSIONAHA.111.186833
57. Huston JM, Tracey KJ. The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy. J Intern Med. 2011;269:45–53. DOI: 10.1111/j.1365-2796.2010.02321.x
58. Anders S, Tanaka M, Kinney DK. Depression as an evolutionary strategy for defense against infection. Brain Behav Immun. 2013;31:9–22. DOI: 10.1016/j.bbi.2012.12.002
59. Tanaka M, Anders S, Kinney DK. Environment, the immune system, and depression: an integrative review and discussion of the infection-defense hypothesis. In: Dietert RR, Luebke RW, editors. Immunotoxicity, immune dysfunction, and chronic disease. Humana Press (Springer), New York. 2012; pp 345–85.
60. Benros ME, Waltoft BL, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry. 2013;70:812–20. DOI: 10.1001/jamapsychiatry.2013.1111
61. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130:226–38. DOI: 10.1016/j.pharmthera.2011.01.014
62. Hornig M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Curr Opin Rheumatol. 2013;25(4):488–95. DOI: 10.1097/BOR.0b013e32836208de
63. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behavior. Nat Rev Neurosci. 2012;13:701–12. DOI: 10.1038/nrn3346
64. Raison CL, Lowry CA, Rook GAW. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry. 2010;67:1211–24. DOI: 10.1001/archgenpsychiatry.2010.161
65. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011;36:2452–9. DOI: 10.1038/npp.2011.132
66. Bonaz B, Picq C, Sinniger V, et al. Vagus nerve stimulation: from epilepsy to the cholinergic anti-inflammatory pathway. Neurogastroenterol Motil. 2013;25:208–21. This paper reviews the involvement of the vagus nerve in the cholinergic anti-inflammatory pathway and the known and potential anti-inflammatory effects of vagus nerve stimulation. DOI: 10.1111/nmo.12076
67. Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex: linking immunity and metabolism. Nat Rev Endocrinol. 2012;8:743–54. This paper reviews the involvement of the vagus nerve in regulation of metabolic homeostasis, and the efferent vagus nerve-mediated control of immune function and proinflammatory response via the cholinergic inflammatory reflex. DOI: 10.1038/nrendo.2012.189
68. Sun Z, Baker W, Hiraki T, Greenberg JH. The effect of right vagus nerve stimulation on focal cerebral ischemia. Brain Stimul. 2012;5:1–10. DOI: 10.1016/j.brs.2011.01.009
69. Ay I, Sorensen AG, Ay H. Vagus nerve stimulation reduces infarct size in rat focal cerebral ischemia: an unlikely role for cerebral blood flow. Brain Res. 2011;1392:110–5. DOI: 10.1016/j.brainres.2011.03.060
70. Huston JM, Gallowitsche-Puerta M, Ochani M, et al. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med. 2007;35:2762–8. DOI: 10.1097/01.CCM.0000288102.15975.BA
71. Aalbers MW, Klinkenberg S, Rijkers K, et al. The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in children with refractory epilepsy: an exploratory study. Neuroimmunomodulation. 2012;19:352–8. DOI: 10.1159/000341402
72. Barone L, Colicchio G, Policicchio D, et al. Effect of vagal nerve stimulation on systemic inflammation and cardiac autonomic function in patients with refractory epilepsy. Neuroimmunomodulation. 2007;14:331–6. DOI: 10.1159/000127360
73. Majoie HJ, Rijkers K, Berfelo MW, et al. Vagus nerve stimulation in refractory epilepsy: effects on pro- and anti-inflammatory cytokines in peripheral blood. Neuroimmunomodulation. 2011;18:52–6. DOI: 10.1159/000315530
74. De Herdt V, Bogaert S, Bracke KR, et al. Effects of vagus nerve stimulation on pro- and anti-inflammatory cytokine induction in patients with refractory epilepsy. J Neuroimmunol. 2009;214:104–8. DOI: 10.1016/j.jneuroim.2009.06.008
75. Corcoran C, Connor TJ, O’Keane V, Garland MR. The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report. Neuroimmunomodulation. 2005;12:307–9. DOI: 10.1159/000087109
76. Moreno J, Gaspar E, Lopez-Bello G, et al. Increase in nitric oxide levels and mitochondrial membrane potential in platelets of untreated patients with major depression. Psychiatry Res. 2013;209:447–52. DOI: 10.1016/j.psychres.2012.12.024
77. Trueba AF, Smith NB, Auchus RJ, Ritz T. Academic exam stress and depressive mood are associated with reductions in exhaled nitric oxide in healthy individuals. Biol Psychol. 2013;93:206–12. DOI: 10.1016/j.biopsycho.2013.01.017
78. Lu DY, Leung YM, Su KP. Interferon-alpha induces nitric oxide synthase expression and haem oxygenase-1 down-regulation in microglia: implications of cellular mechanism of IFN-alpha-induced depression. Int J Neuropsychopharmacol. 2013;16:433–44. DOI: 10.1017/S1461145712000338
79. Leonard BE. Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:261–7. This review summarizes evidence that chronic low-grade inflammation plays an important role in the pathology of depression. DOI: 10.1016/j.pnpbp.2013.10.018
80. Lotrich F. Inflammatory cytokines, growth factors, and depression. Curr Pharm Des. 2012;18:5920–35. DOI: 10.2174/138161212803523680
81. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41. DOI: 10.1001/2013.jamapsychiatry.4
82. Celano CM, Huffman JC. Depression and cardiac disease: a review. Cardiol Rev. 2011;19:130–42. DOI: 10.1097/CRD.0b013e31820e8106
83. Rustad JK, Stern TA, Hebert KA, Musselman DL. Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature. Prim Care Companion CNS Disord. 2013;15, PCC.13r01511. doi:10.4088/PCC.13r01511.
84. Martin JLR, Martin-Sanchez E. Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study design. Eur Psychiatry. 2012;27:147–55. DOI: 10.1016/j.eurpsy.2011.07.006
85. Olanchanski N, McInnis Myers M, Halseth M, et al. The economic burden of treatment-resistant depression. Clin Ther. 2013;35:512–22. DOI: 10.1016/j.clinthera.2012.09.001
86. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17. DOI: 10.1176/appi.ajp.163.11.1905
87. Shen MJ, Shinohara T, Park HW, et al. Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines. Circulation. 2011;123:2204–12. DOI: 10.1161/CIRCULATIONAHA.111.018028
88. Zhang Y, Mazgalev TN. Arrhythmias and vagus nerve stimulation. Heart Fail Rev. 2011;16:147–61. DOI: 10.1007/s10741-010-9178-2
89. Yu L, Scherlag BJ, Li S, et al. Low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve: a noninvasive approach to treat the initial phase of atrial fibrillation. Heart Rhythm. 2013;10:428–35. DOI: 10.1016/j.hrthm.2012.11.019
90. Kreuzer PM, Landgrebe J, Husser O, et al. Transcutaneous vagus nerve stimulation: retrospective assessment of cardiac safety in a pilot study. Front Psychiatry. 2012;3:70. doi:10.3389/fpsyt.2012.00070. DOI: 10.3389/fpsyt.2012.00070